RDY — Dr. Reddy's Laboratories Limited American Depositary Shares
Healthcare · Drug Manufacturers - Specialty & Generic
- Latest Close
- $13.67
- 30-Day Move
- -3.0%
- Market Cap
- $11.9B
- Shares Outstanding
- 832,580,855
- P/E Ratio
- 19.67
- P/B Ratio
- 2.84
Dr. Reddy's Laboratories Limited American Depositary Shares
A read-only Alphactor snapshot forDr. Reddy's Laboratories Limited American Depositary Shares. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$13.67
30-Day Move
-3.0%
Market Cap
$11.9B
Shares Outstanding
832,580,855
P/E Ratio
19.67
P/B Ratio
2.84
$13.67
-3.0%last 90 delayed daily bars
90D High
$14.80
90D Low
$12.77
Avg Volume
2,002,662
Gross margin is running at 65.8%, which gives a quick read on operating quality before you open the full model.
Net margin is 16.1%, useful for comparing RDY against peers in Healthcare.
RDY is down 3.0% over the last 30 trading days shown on this page.
Latest operating income is $14.3B, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$1008.98
Rule of 40
20.3%
Latest Close
$13.67
30-Day Move
-3.0%
Market Cap
$11.9B
Shares Outstanding
832,580,855
P/E Ratio
19.67
P/B Ratio
2.84
ROE
16.9%
ROA
11.4%
Gross Margin
65.8%
Operating Margin
17.7%
Net Margin
16.1%
Debt / Equity
0.14
Current Ratio
1.92
Dividend Yield
60.9%
Latest Revenue
$87.3B
Revenue
$87.3B
Gross Profit
$46.8B
Operating Income
$14.3B
Net Income
$12.1B
Gross Margin
6576.0%
Net Margin
1606.0%
Current Ratio
1.92
Debt / Equity
0.14
Fair Value
$1008.98
Upside / Downside
+7281.0%
Signal
Undervalued
Implied Growth
-19.0%
DCF
$355.87
EPV
$754.67
EV/Rev
$1916.41
Growth Assumption
14.9%
Discount Rate
8.4%
Terminal Growth
2.0%
Base FCF
$12.0B
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative growth / decline priced in
Altman Z
2.38
Grey
Piotroski
3
Weak (0-3)
Cash Conversion
0.82x
Rule of 40
20.3%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $214.4B | $35.9B | $23.6B | $9.1B |
| 2023-12-31 | $245.9B | $59.1B | $45.1B | $40.0B |
| 2024-12-31 | $279.2B | $65.3B | $55.7B | $18.0B |
| 2025-12-31 | $325.5B | $72.0B | $56.5B | $12.0B |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Qube Research & Technologies
Filed 2025-08-14
--
--
Two Sigma Advisers
Filed 2025-08-14
--
--
BlackRock
Filed 2024-05-10
$160M
--
Renaissance Technologies
Filed 2025-08-13
$135M
-2.0%
Vanguard Group
Filed 2025-08-11
$75M
-0.6%
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.